PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of $0.20, $1.32 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $211 million versus the consensus estimate of $174.39 million.

GUIDANCE:

PTC Therapeutics sees FY2025 revenue of $750-800 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.